Gilead Sciences Announces Third Quarter 2013 Financial Results

  Gilead Sciences Announces Third Quarter 2013 Financial Results

  - Total Revenues of $2.78 billion, Up 15 percent over Third Quarter 2012 -
                     - Revised Full Year 2013 Guidance -

Business Wire

FOSTER CITY, Calif. -- October 29, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations
for the quarter ended September 30, 2013. Total revenues for the third quarter
of 2013 increased 15 percent to $2.78 billion, from $2.43 billion for the
third quarter of 2012. Product sales increased 15 percent to $2.71 billion for
the third quarter of 2013 compared to $2.36 billion for the third quarter of
2012. Net income for the third quarter of 2013 was $788.6 million, or $0.47
per diluted share compared to $675.5 million, or $0.43 per diluted share for
the third quarter of 2012. Non-GAAP net income for the third quarter of 2013,
which excludes acquisition-related, restructuring and stock-based compensation
expenses, was $879.1 million, or $0.52 per diluted share compared to $788.9
million, or $0.50 per diluted share for the third quarter of 2012.

                  Three Months Ended             Nine Months Ended
                   September 30,                   September 30,
(In thousands,
except per share  2013           2012            2013           2012
amounts)
Product sales      $ 2,709,652     $ 2,357,978     $ 7,760,505     $ 6,887,560
Royalty,
contract and       73,181         68,619         321,357        226,672
other revenues
Total revenues     $ 2,782,833    $ 2,426,597    $ 8,081,862    $ 7,114,232
                                                                   
Net income
attributable to    $ 788,606       $ 675,505       $ 2,283,397     $ 1,829,025
Gilead
Non-GAAP net
income             $ 879,081       $ 788,940       $ 2,520,749     $ 2,260,606
attributable to
Gilead
                                                                   
Diluted EPS        $ 0.47          $ 0.43          $ 1.35          $ 1.17
Non-GAAP diluted   $ 0.52          $ 0.50          $ 1.49          $ 1.44
EPS
                                                                     

Product Sales

Product sales were driven primarily by growth in Gilead's antiviral franchise
during the third quarter of 2013. Significantly contributing to the increase
were sales of Stribild^® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine
200 mg/tenofovir disoproxil fumarate 300 mg) which launched in the third
quarter of 2012 and sales of Complera^®/Eviplera^® (emtricitabine 200
mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg). Product sales for
the third quarter increased 20 percent in the U.S. and 5 percent in Europe
compared to the third quarter of 2012.

Antiviral Product Sales

Antiviral product sales increased 14 percent to $2.33 billion for the third
quarter of 2013, up from $2.04 billion for the third quarter of 2012,
reflecting sales growth of 19 percent in the U.S. and 6 percent in Europe. The
increase reflects strong underlying demand for our new single tablet regimen
products, specifically Stribild and Complera/Eviplera.

                   Three Months Ended                   Nine Months Ended           
                    September 30,                          September 30,
(In thousands,                                    %
except              2013          2012           Change   2013          2012           % Change
percentages)
Antiviral product   $ 2,326,727    $ 2,035,833    14   %   $ 6,700,052    $ 5,973,922    12    %
sales
Atripla             899,669        865,378        4    %   2,714,850      2,656,997      2     %
Truvada             813,652        804,190        1    %   2,321,673      2,348,386      (1    )%
Viread              231,555        214,909        8    %   692,075        622,016        11    %
Complera/Eviplera   210,736        99,297         112  %   547,608        224,386        144   %
Stribild            143,953        17,511         722  %   335,495        17,511         1,816 %
                                                                                               

Cardiovascular Product Sales

Cardiovascular product sales increased 25 percent to $250.9 million for the
third quarter of 2013.

                Three Months Ended               Nine Months Ended       
                 September 30,                      September 30,
(In thousands,                             %                                  %
except           2013        2012         Change   2013        2012         Change
percentages)
Cardiovascular   $ 250,887    $ 200,120    25  %    $ 700,134    $ 567,798    23  %
product sales
Letairis         135,072      105,054      29  %    381,436      293,976      30  %
Ranexa           115,815      95,066       22  %    318,698      273,822      16  %
                                                                                  

Operating Expenses and Other

Non-GAAP research and development (R&D) expenses increased due to the
progression of Gilead's clinical studies, particularly in oncology and HIV.
Non-GAAP selling, general and administrative (SG&A) expenses increased
primarily due to the ongoing growth and expansion of Gilead's business in
preparation for the anticipated launch of sofosbuvir.

Interest expense decreased primarily due to the maturity of the May 2013
convertible senior notes and the repayment of $850.0 million in bank debt
issued in connection with the acquisition of Pharmasset Inc.

                    Three Months Ended         Nine Months Ended
                     September 30,               September 30,
(In thousands,
except               2013         2012          2013           2012
percentages)
Non-GAAP research
and development      $ 488,535     $ 383,553     $ 1,436,282     $ 1,086,289
expenses
Non-GAAP selling,
general and          $ 376,841     $ 287,205     $ 1,086,241     $ 893,677
administrative
expenses
                                                                 
Non-GAAP Interest    $ (73,949 )   $ (89,322 )   $ (233,744  )   $ (267,677  )
expense

Note: Non-GAAP R&D, SG&A and interest expenses exclude the impact of
acquisition-related, restructuring and stock-based compensation expenses where
applicable.

Net Foreign Currency Exchange Impact

The net foreign currency exchange impact on third quarter 2013 product sales
and pre-tax earnings was an unfavorable $17.5 million and $15.9 million,
respectively, compared to the third quarter of 2012.

Cash, Cash Equivalents and Marketable Securities

As of September30, 2013, Gilead had $2.76 billion of cash, cash equivalents
and marketable securities compared to $2.58 billion as of December31, 2012.
During the first nine months of 2013, Gilead generated $2.38 billion in
operating cash flow.

Full Year 2013 Guidance

Gilead revised its full year 2013 guidance, which it initially provided on
February 4, 2013 and reiterated on July 25, 2013:

                                          Initially provided    Updated
(In millions, except percentages and      February 4, 2013;
per share amounts)                                            October 29,
                                          Reiterated July 25,   2013
                                          2013
Net Product Sales                         $10,000 - $10,200     $10,300 -
                                                                $10,400
Non-GAAP*
Product Gross Margin                      74% - 76%             74% - 76%
R&D                                       $1,800 - $1,900       $1,950 -
                                                                $2,000
SG&A                                      $1,550 - $1,650       $1,500 -
                                                                $1,550
Effective Tax Rate                        26% - 28%             26% - 27%
                                                                
Diluted EPS Impact of
Acquisition-Related, Restructuring and    $0.21 - $0.24         $0.21 - $0.24
Stock-Based Compensation Expenses

* Non-GAAP product gross margin, expense and effective tax rate exclude the
impact of acquisition-related, restructuring and stock-based compensation
expenses, where applicable.

Product & Pipeline Updates Announced by Gilead During the Third Quarter of
2013 Include:

Antiviral Program

  *Results from a Phase 2 study (Study 102) evaluating an investigational
    once-daily single tablet regimen containing tenofovir alafenamide (TAF)
    for the treatment of HIV-1 infection. At 48 weeks, a regimen of
    elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/TAF 10 mg was
    found to be similar to Stribild based on the percentage of patients with
    HIV RNA levels less than 50 copies/mL, and was associated with more
    favorable renal and bone safety markers. These results were presented at
    the 53^rd Interscience Conference on Antimicrobial Agents and Chemotherapy
    in Denver.
  *Granting of marketing authorization by the European Commission for
    once-daily Tybost^®, a pharmacokinetic enhancer that boosts blood levels
    of certain HIV medicines. Tybost is indicated as a boosting agent for the
    HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg
    once daily as part of antiretroviral combination therapy in adults with
    HIV-1 infection. This approval allows for the marketing of Tybost in all
    28 countries of the European Union.

Oncology Program

  *Submission of a New Drug Application to the U.S. Food and Drug
    Administration for marketing approval to support the use of idelalisib, an
    investigational, targeted, oral inhibitor of PI3K delta, for the treatment
    of indolent non-Hodgkin’s lymphoma (iNHL) for patients with iNHL that is
    refractory (non-responsive) to rituximab and to
    alkylating-agent-containing chemotherapy.

Conference Call

At 4:30 p.m. Eastern Time today, Gilead's management will host a conference
call and a simultaneous webcast to discuss results from its third quarter 2013
as well as provide a general business update. To access the webcast live via
the internet, please connect to the company's website at www.gilead.com 15
minutes prior to the conference call to ensure adequate time for any software
download that may be needed to hear the webcast. Alternatively, please call
1-866-825-3209 (U.S.) or 1-617-213-8061 (international) and dial the
participant passcode 95755257 to access the call.

A replay of the webcast will be archived on the company's website for one
year, and a phone replay will be available approximately two hours following
the call through November 1, 2013. To access the phone replay, please call
1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the
participant passcode 81078378.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and
commercializes innovative therapeutics in areas of unmet medical need. The
company's mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Asia-Pacific.

Non-GAAP Financial Information

Gilead has presented certain financial information in accordance with U.S.
generally accepted accounting principles (GAAP) and also on a non-GAAP basis.
Management believes this non-GAAP information is useful for investors, when
considered in conjunction with Gilead's GAAP financial statements, because
management uses such information internally for its operating, budgeting and
financial planning purposes. Non-GAAP information is not prepared under a
comprehensive set of accounting rules and should only be used to supplement an
understanding of Gilead's operating results as reported under GAAP. A
reconciliation between GAAP and non-GAAP financial information is provided in
the table on pages 7 and 8.

Forward-looking Statements

Statements included in this press release that are not historical in nature
are forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Gilead cautions readers that forward-looking
statements are subject to certain risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties include:
Gilead's ability to achieve its anticipated full year 2013 financial results;
Gilead's ability to sustain growth in revenues for its antiviral,
cardiovascular and respiratory programs; availability of funding for state
AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP
purchases driven by federal and state grant cycles which may not mirror
patient demand and may cause fluctuations in Gilead's earnings; the
possibility of unfavorable results from clinical trials involving sofosbuvir,
the fixed-dose combination of sofosbuvir/ledipasvir, TAF and idelalisib; the
levels of inventory held by wholesalers and retailers which may cause
fluctuations in Gilead's earnings; Gilead's ability to submit NDAs for new
product candidates in the timelines currently anticipated, including the
fixed-dose combination of sofosbuvir/ledipasvir for the treatment of HCV;
Gilead's ability to receive regulatory approvals in a timely manner or at all,
for new and current products, including sofosbuvir for the treatment of HCV
and idelalisib for iNHL; Gilead's ability to successfully commercialize its
products, including Stribild and Tybost; Gilead's ability to successfully
develop its respiratory, cardiovascular and oncology/inflammation programs;
safety and efficacy data from clinical studies may not warrant further
development of Gilead's product candidates, including sofosbuvir, the
fixed-dose combination of sofosbuvir/ledipasvir, TAF and idelalisib; the
potential for additional austerity measures in European countries that may
increase the amount of discount required on Gilead's products; fluctuations in
the foreign exchange rate of the U.S. dollar that may cause an unfavorable
foreign currency exchange impact on Gilead's future revenues and pre-tax
earnings; and other risks identified from time to time in Gilead's reports
filed with the U.S. Securities and Exchange Commission (SEC). In addition,
Gilead makes estimates and judgments that affect the reported amounts of
assets, liabilities, revenues and expenses and related disclosures. Gilead
bases its estimates on historical experience and on various other
market-specific and other relevant assumptions that it believes to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ
significantly from these estimates. You are urged to consider statements that
include the words may, will, would, could, should, might, believes, estimates,
projects, potential, expects, plans, anticipates, intends, continues,
forecast, designed, goal, or the negative of those words or other comparable
words to be uncertain and forward-looking. Gilead directs readers to its press
releases, Quarterly Report on Form 10-Q for the quarter ended June 30, 2013
and other subsequent disclosure documents filed with the SEC. Gilead claims
the protection of the Safe Harbor contained in the Private Securities
Litigation Reform Act of 1995 for forward-looking statements. All
forward-looking statements are based on information currently available to
Gilead, and Gilead assumes no obligation to update any such forward-looking
statements.

 Gilead owns or has rights to various trademarks, copyrights and trade names
                used in our business, including the following:
 GILEAD^®, GILEAD SCIENCES^®, STRIBILD^®, COMPLERA^®, EVIPLERA^®, TRUVADA^®,
 VIREAD^®, TYBOST^®, HEPSERA^®, EMTRIVA^®, LETAIRIS^®, RANEXA^®, AMBISOME^®,
                           CAYSTON^® and VISTIDE^®.

ATRIPLA^® is a registered trademark belonging to Bristol-Myers Squibb& Gilead
                                Sciences, LLC.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or
call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

                                                                  
                                                                            
GILEAD SCIENCES, INC.
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(in thousands, except per share amounts)
                                                                            
                    Three Months Ended                    Nine Months Ended
                    September 30,                         September 30,
                     2013            2012              2013            2012      
Revenues:
Product sales       $ 2,709,652       $ 2,357,978         $ 7,760,505       $ 6,887,560
Royalty,
contract and         73,181          68,619            321,357         226,672   
other revenues
Total revenues       2,782,833       2,426,597         8,081,862       7,114,232 
Costs and
expenses:
Cost of goods         681,868           597,269             2,000,979         1,795,545
sold
Research and          546,244           465,831             1,567,778         1,320,286
development
Selling,
general and          406,860         319,583           1,186,147       1,095,209 
administrative
Total costs          1,634,972       1,382,683         4,754,904       4,211,040 
and expenses
Income from           1,147,861         1,043,914           3,326,958         2,903,192
operations
Interest              (73,949   )       (89,322   )         (233,744  )       (275,010  )
expense
Other income         5,777           (3,505    )        2,222           (38,665   )
(expense), net
Income before
provision for         1,079,689         951,087             3,095,436         2,589,517
income taxes
Provision for        294,473         280,052           824,892         774,877   
income taxes
Net income            785,216           671,035             2,270,544         1,814,640
Net loss
attributable
to                   3,390           4,470             12,853          14,385    
noncontrolling
interest
Net income
attributable        $ 788,606        $ 675,505          $ 2,283,397      $ 1,829,025 
to Gilead
Net income per
share attributable
to Gilead common    $ 0.51           $ 0.45             $ 1.50           $ 1.21      
stockholders

- basic
Net income per
share attributable
to Gilead common    $ 0.47           $ 0.43             $ 1.35           $ 1.17      
stockholders

- diluted
Shares used in
per share            1,532,105       1,514,770         1,526,847       1,514,064 
calculation -
basic
Shares used in
per share            1,691,898       1,584,608         1,689,647       1,567,648 
calculation -
diluted


GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)
(in thousands, except percentages and per share amounts)
                                                                     
                           Three Months Ended                 Nine Months Ended
                           September 30,                      September 30,
                            2013           2012            2013            2012      
Cost of goods sold
reconciliation:
GAAP cost of goods         $ 681,868        $ 597,269         $ 2,000,979       $ 1,795,545
sold
Stock-based
compensation                 (1,823  )        (1,864  )         (6,296    )       (6,084    )
expenses
Acquisition
related-amortization        (21,264 )       (15,837 )        (63,792   )      (47,509   )
of purchased
intangibles
Non-GAAP cost of           $ 658,781       $ 579,568        $ 1,930,891      $ 1,741,952 
goods sold
                                                                                
Product gross margin
reconciliation:
GAAP product gross           74.8    %        74.7    %         74.2      %       74.0      %
margin
Stock-based
compensation                 0.1     %        0.1     %         0.1       %       0.1       %
expenses
Acquisition
related-amortization        0.8     %       0.7     %        0.8       %      0.7       %
of purchased
intangibles
Non-GAAP product            75.7    %       75.5    %        75.1      %      74.8      %
gross margin^(1)
                                                                                
Research and
development expenses
reconciliation:
GAAP research and          $ 546,244        $ 465,831         $ 1,567,778       $ 1,320,286
development expenses
Stock-based
compensation                 (27,740 )        (23,236 )         (79,261   )       (162,214  )
expenses
Restructuring                31               (232    )         (4,793    )       (7,322    )
expenses
Acquisition
related-transaction          —                —                 —                 (345      )
costs
Acquisition
related-contingent          (30,000 )       (58,810 )        (47,442   )      (64,116   )
consideration
remeasurement
Non-GAAP research
and development            $ 488,535       $ 383,553        $ 1,436,282      $ 1,086,289 
expenses
                                                                                
Selling, general and
administrative
expenses
reconciliation:
GAAP selling,
general and                $ 406,860        $ 319,583         $ 1,186,147       $ 1,095,209
administrative
expenses
Stock-based
compensation                 (33,010 )        (29,364 )         (94,736   )       (177,237  )
expenses
Restructuring                2,972            (2,792  )         2,534             (13,199   )
expenses
Acquisition
related-transaction          300              (222    )         (6,860    )       (11,096   )
costs
Acquisition
related-amortization        (281    )       —               (844      )      —         
of purchased
intangibles
Non-GAAP selling,
general and                $ 376,841       $ 287,205        $ 1,086,241      $ 893,677   
administrative
expenses
                                                                                
Operating margin
reconciliation:
GAAP operating               41.2    %        43.0    %         41.2      %       40.8      %
margin
Stock-based
compensation                 2.2     %        2.2     %         2.2       %       4.9       %
expenses
Restructuring                (0.1    )%       0.1     %         0.0       %       0.3       %
expenses
Acquisition
related-transaction          0.0     %        0.0     %         0.1       %       0.2       %
costs
Acquisition
related-amortization         0.8     %        0.7     %         0.8       %       0.7       %
of purchased
intangibles
Acquisition
related-contingent          1.1     %       2.4     %        0.6       %      0.9       %
consideration
remeasurement
Non-GAAP operating          45.2    %       48.5    %        44.9      %      47.7      %
margin^(1)
                                                                                
Interest expense
reconciliation:
GAAP interest              $ (73,949 )      $ (89,322 )       $ (233,744  )     $ (275,010  )
expense
Acquisition
related-transaction         —              —               —               7,333     
costs
Non-GAAP interest          $ (73,949 )      $ (89,322 )       $ (233,744  )     $ (267,677  )
expense
                                                                                
Net income
attributable to
Gilead
reconciliation:
GAAP net income
attributable to            $ 788,606        $ 675,505         $ 2,283,397       $ 1,829,025
Gilead, net of tax
Stock-based
compensation                 46,576           39,442            132,335           304,282
expenses
Restructuring                (2,076  )        2,165             3,048             14,937
expenses
Acquisition
related-transaction          (300    )        123               6,860             13,665
costs
Acquisition
related-amortization         16,275           11,462            47,667            34,581
of purchased
intangibles
Acquisition
related-contingent          30,000         60,243          47,442          64,116    
consideration
remeasurement
Non-GAAP net income
attributable to            $ 879,081       $ 788,940        $ 2,520,749      $ 2,260,606 
Gilead, net of tax


GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)
(in thousands, except percentages and per share amounts)
                                                                        
                           Three Months Ended                    Nine Months Ended
                           September 30,                         September 30,
                            2013            2012              2013            2012      
Diluted earnings per
share
reconciliation:
GAAP diluted               $ 0.47            $ 0.43              $ 1.35            $ 1.17
earnings per share
Stock-based
compensation                 0.03              0.02                0.08              0.19
expenses
Restructuring                (0.00     )       0.00                0.00              0.01
expenses
Acquisition
related-transaction          (0.00     )       0.00                0.00              0.01
costs
Acquisition
related-amortization         0.01              0.01                0.03              0.02
of purchased
intangibles
Acquisition
related-contingent          0.02            0.04              0.03            0.04      
consideration
remeasurement
Non-GAAP diluted
earnings per               $ 0.52           $ 0.50             $ 1.49           $ 1.44      
share^(1)
                                                                                   
Shares used in per
share calculation
(diluted)
reconciliation:
GAAP shares used in
per share                    1,691,898         1,584,608           1,689,647         1,567,648
calculation
(diluted)
Share impact of
current stock-based         (1,139    )      (2,620    )        (1,281    )      (2,854    )
compensation rules
Non-GAAP shares used
in per share                1,690,759       1,581,988         1,688,366       1,564,794 
calculation
(diluted)
                                                                                   
Non-GAAP adjustment
summary:
Cost of goods sold         $ 23,087          $ 17,701            $ 70,088          $ 53,593
adjustments
Research and
development expenses         57,709            82,278              131,496           233,997
adjustments
Selling, general and
administrative               30,019            32,378              99,906            201,532
expenses adjustments
Interest expense            —               —                 —               7,333     
adjustments
Total non-GAAP
adjustments before           110,815           132,357             301,490           496,455
tax
Income tax effect           (20,340   )      (18,922   )        (64,138   )      (64,874   )
Total non-GAAP
adjustments after          $ 90,475         $ 113,435          $ 237,352        $ 431,581   
tax
                                                                                   
^(1) Amounts may not
sum due to rounding.


GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
                                                         
                                         September 30,           December 31,
                                           2013                   2012^(1)
                                         (unaudited)
Cash, cash equivalents and               $  2,755,557            $  2,582,086
marketable securities
Accounts receivable, net                    1,971,926               1,751,388
Inventories                                 1,946,048               1,744,982
Property, plant and equipment,              1,133,032               1,100,259
net
Intangible assets, net                      12,034,457              11,736,393
Goodwill                                    1,188,157               1,060,919
Other assets                               1,439,251              1,263,811
Total assets                             $  22,468,428           $  21,239,838
                                                                 
Current liabilities                      $  4,895,124            $  4,270,020
Long-term liabilities                       6,380,831               7,418,949
Stockholders’ equity^(2)                   11,192,473             9,550,869
Total liabilities and                    $  22,468,428           $  21,239,838
stockholders’ equity
                                                                 
^(1) Derived from the audited consolidated financial statements as of December
31, 2012.
^(2) As of September 30, 2013, there were 1,534,028 shares of common stock
issued and outstanding.


GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
(in thousands)
                                                           
                    Three Months Ended                Nine Months Ended
                    September 30,                     September 30,
                     2013           2012             2013           2012
Antiviral
products:
Atripla –           $ 575,533       $ 539,797         $ 1,740,689     $ 1,672,676
U.S.
Atripla –             256,853         270,273           805,848         821,094
Europe
Atripla –
Other                67,283         55,308           168,313        163,227
International
                     899,669        865,378          2,714,850      2,656,997
                                                                      
Truvada –             430,173         414,452           1,153,575       1,180,791
U.S.
Truvada –             313,963         329,936           970,982         980,626
Europe
Truvada –
Other                69,516         59,802           197,116        186,969
International
                     813,652        804,190          2,321,673      2,348,386
                                                                      
Viread – U.S.         108,718         98,969            305,311         282,737
Viread –              86,177          81,962            262,425         250,955
Europe
Viread –
Other                36,660         33,978           124,339        88,324
International
                     231,555        214,909          692,075        622,016
                                                                      
Complera /
Eviplera –            126,888         82,099            350,372         195,742
U.S.
Complera /
Eviplera –            74,025          14,306            172,288         24,771
Europe
Complera /
Eviplera –           9,823          2,892            24,948         3,873
Other
                     210,736        99,297           547,608        224,386
                                                                      
Stribild –            134,700         17,511            323,639         17,511
U.S.
Stribild –            7,911           —                 9,759           —
Europe
Stribild –
Other                1,342          —                2,097          —
International
                     143,953        17,511           335,495        17,511
                                                                      
Hepsera –             8,578           12,615            31,399          33,596
U.S.
Hepsera –             9,760           11,999            30,251          41,384
Europe
Hepsera –
Other                1,978          2,705            6,545          7,827
International
                     20,316         27,319           68,195         82,807
                                                                      
Emtriva –             5,127           4,717             14,424          13,580
U.S.
Emtriva –             1,560           1,617             4,895           5,169
Europe
Emtriva –
Other                159            895              837            3,070
International
                     6,846          7,229            20,156         21,819
                                                                      
Total
Antiviral             1,389,717       1,170,160         3,919,409       3,396,633
products –
U.S.
Total
Antiviral             750,249         710,093           2,256,448       2,123,999
products –
Europe
Total
Antiviral
products –           186,761        155,580          524,195        453,290
Other
International
                     2,326,727      2,035,833        6,700,052      5,973,922
                                                                      
Letairis              135,072         105,054           381,436         293,976
Ranexa                115,815         95,066            318,698         273,822
AmBisome              97,812          87,448            258,224         255,865
Other                34,226         34,577           102,095        89,975
products
                     382,925        322,145          1,060,453      913,638
                                                                      
Total product       $ 2,709,652     $ 2,357,978       $ 7,760,505     $ 6,887,560
sales

Contact:

Gilead Sciences, Inc.
Investors
Robin Washington, 650-522-5688
Patrick O'Brien, 650-522-1936
or
Media
Cara Miller, 650-522-1616
 
Press spacebar to pause and continue. Press esc to stop.